The role of FKBP5 in cancer aetiology and chemoresistance.
FK506 binding protein 51 (FKBP51, also called FKBP5) belongs to a family of immunophilins, FK506 binding proteins (FKBPs). Members of this family are targets for drugs such as rapamycin and cyclosporine. Although FKBP5 shares characteristics with other FKBPs, it also has unique features, especially its role in the regulation of multiple signalling pathways and in tumourigenesis and chemoresistance. In this review, we will focus on the recently discovered role of FKBP5 in cancer aetiology and response to antineoplastic therapy.
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
L
L
Li
Z
Z
Lou
L
L
Wang
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D018841:HSP90 Heat-Shock Proteins / Q000502:physiology*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000209:etiology*; D015398:Signal Transduction; D022021:Tacrolimus Binding Proteins / Q000502:physiology*; D000099159:Tacrolimus Binding Protein 5
D000970:Antineoplastic Agents; D018841:HSP90 Heat-Shock Proteins; D022021:Tacrolimus Binding Proteins; D000099159:Tacrolimus Binding Protein 5